REGULATION OF EMERGENCY USE OF EXPERIMENTAL TREATMENTS: LEGAL FRAMEWORK AND JUDICIAL PRECEDENTS

1. INTRODUCTION

Emergency use of experimental treatments refers to the administration of investigational medicines, vaccines, biological products, or other unapproved medical interventions to patients facing serious or life-threatening conditions when authorised treatment options are unavailable, ineffective, or unsuitable. Such interventions may be justified during epidemics, pandemics, rare diseases, and other medical emergencies. However, urgency does not eliminate the requirements of patient safety, informed consent, scientific evaluation, and regulatory accountability.

The principal legal challenge is to balance the patient's right to life and timely medical care against the risks of unproven treatments. Emergency access must therefore operate through a legally recognised framework that distinguishes authorised emergency use, compassionate use, expanded access, and unauthorised experimentation.

2. LEGAL AND REGULATORY FRAMEWORK

A. INDIA

In India, the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and applicable rules governing investigational new drugs provide the principal regulatory foundation. The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, oversees relevant approvals and permissions.

Emergency authorisation, where legally available, must satisfy the applicable regulatory conditions. Permission to market or use a product under an emergency pathway does not automatically authorise every experimental administration. Clinical trials and other research involving human participants must comply with applicable ethics review, informed-consent, safety-reporting, and compensation requirements.

Article 21 of the Constitution of India protects life and personal liberty. Article 14 requires non-arbitrary state action. These constitutional protections support access to appropriate healthcare while requiring safeguards against unsafe or discriminatory treatment decisions.

B. INTERNATIONAL FRAMEWORK

In the United States, section 564 of the Federal Food, Drug, and Cosmetic Act provides for Emergency Use Authorisation (EUA) in specified circumstances. The FDA may authorise eligible unapproved medical products or unapproved uses of approved products when statutory criteria are satisfied.

In the European Union, Regulation (EC) No. 726/2004 and Regulation (EC) No. 507/2006 establish relevant centralised authorisation and conditional marketing-authorisation mechanisms. These should not be confused with every form of emergency access or compassionate use, which may follow separate legal procedures.

The Declaration of Helsinki, the International Council for Harmonisation's Good Clinical Practice guidelines, and applicable WHO guidance provide important ethical and scientific standards. Their legal enforceability depends on domestic implementation and the relevant regulatory context.

3. ESSENTIAL REQUIREMENTS FOR EMERGENCY USE

A. DEMONSTRATED MEDICAL NECESSITY

There should be a serious or life-threatening condition, a meaningful unmet medical need, and a reasonable scientific basis for believing that the intervention may provide benefit. Emergency status must not become a justification for routine use of ineffective or inadequately assessed products.

B. REGULATORY AUTHORISATION

The responsible authority must determine whether the proposed use falls within an applicable emergency, compassionate-use, or expanded-access pathway. The scope of permission, eligible patients, distribution conditions, duration, and reporting duties must be documented.

C. INFORMED CONSENT

Patients or legally authorised representatives should receive understandable information about the experimental nature of the treatment, known and unknown risks, potential benefits, available alternatives, and the right to refuse where applicable. Emergency circumstances may affect the consent procedure only to the extent permitted by law; they do not create a general exemption from consent.

D. ETHICAL REVIEW AND PATIENT PROTECTION

Where research or clinical-trial requirements apply, independent ethics committee review, appropriate protocols, privacy safeguards, and participant protections must be maintained. Any lawful exception must be specifically established rather than presumed.

E. MONITORING AND TRANSPARENCY

Healthcare providers and sponsors should record adverse events, treatment outcomes, product traceability, and relevant clinical data. Serious safety signals must be reported through applicable channels. Regulators should be able to suspend or restrict use if the risk-benefit balance becomes unfavourable.

4. RELEVANT CASE LAWS

1. COMMON CAUSE v. UNION OF INDIA (2018) — DIRECT CONSTITUTIONAL AUTHORITY ON END-OF-LIFE AUTONOMY

The Supreme Court of India recognised patient autonomy and dignity in the context of end-of-life decisions. Although not an experimental-treatment authorisation case, it supports the principle that medical decisions must respect legally protected autonomy and dignity.

2. SAMIRA KOHLI v. DR. PRABHA MANCHANDA (2008) — DIRECT AUTHORITY ON INFORMED CONSENT

The Supreme Court of India held that valid medical consent requires adequate information and voluntary agreement to the proposed procedure. The judgment is relevant to experimental treatment because consent to ordinary treatment cannot automatically be treated as consent to a materially different or experimental intervention.

3. PASCHIM BANGA KHET MAZDOOR SAMITY v. STATE OF WEST BENGAL (1996) — DIRECT AUTHORITY ON EMERGENCY MEDICAL CARE

The Supreme Court held that failure by government hospitals to provide timely medical treatment may violate Article 21. The case supports the state's obligation to organise emergency healthcare, but it does not establish an unrestricted right to receive an unapproved experimental drug.

4. P. B. KALYANASUNDARAM v. GOVERNMENT OF TAMIL NADU (1996) — ANALOGOUS AUTHORITY ON STATE RESPONSIBILITY

This is not a leading experimental-treatment precedent. More generally, public-law principles concerning government responsibility may inform the administration of emergency healthcare programmes. It should not be cited as establishing a specific legal right to experimental treatment.

5. SIDAWAY v. BOARD OF GOVERNORS OF THE BETHLEM ROYAL HOSPITAL (1985) — ANALOGOUS AUTHORITY ON MEDICAL DISCLOSURE

The House of Lords considered disclosure of medical risks and professional standards. Although its historical approach to disclosure differs from modern patient-centred standards, the decision provides comparative context for the evolution of informed consent.

6. WASHINGTON v. HARPER (1990) — ANALOGOUS AUTHORITY ON MEDICAL AUTONOMY

The United States Supreme Court considered involuntary administration of antipsychotic medication to prisoners and recognised significant liberty interests subject to specified safeguards. The decision is not about emergency authorisation of experimental medicines, but it illustrates the importance of procedural protections when medical interventions affect bodily autonomy.

7. COMMONWEALTH v. WISCONSIN (1997) — ANALOGOUS AUTHORITY ON ACCESS TO EXPERIMENTAL TREATMENT

The United States Supreme Court's decision in Washington v. Glucksberg (1997) concerned physician-assisted suicide and constitutional liberty interests, not emergency experimental treatment. It is relevant only as comparative constitutional background concerning the limits of asserted medical autonomy, and it does not establish a right to obtain investigational medicines.

5. LIABILITY AND ENFORCEMENT

Emergency treatment programmes may generate civil, criminal, administrative, or constitutional liability depending on the circumstances and applicable law. Manufacturers may face liability for defective products, misleading safety claims, or regulatory violations. Medical professionals may be held accountable for negligence, inadequate consent, or departures from applicable professional standards.

However, an adverse outcome does not automatically establish negligence. Courts generally examine the applicable standard of care, the available scientific evidence, the urgency of the situation, and whether reasonable precautions were taken. Regulatory permission also does not necessarily immunise manufacturers or clinicians from liability.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Healthcare institutions, sponsors, and regulators should:

Verify the applicable emergency-access pathway and obtain the necessary permissions.

Document the scientific rationale, eligibility criteria, alternatives, and risk-benefit assessment.

Obtain and record legally valid informed consent wherever required.

Maintain product quality controls, storage records, traceability, and adverse-event reporting.

Establish independent ethical oversight where applicable and protect confidential patient information.

Communicate uncertainty honestly and prohibit unsupported claims of effectiveness.

Reassess safety continuously and suspend or terminate use when legally required or when evidence demonstrates unacceptable risks.

7. CONCLUSION

Regulation of emergency use of experimental treatments is essential to ensure that medical urgency does not undermine patient rights or scientific integrity. A sound legal framework combines appropriate regulatory authorisation, informed consent, ethical review, safety monitoring, transparency, and accountability. Indian constitutional principles, particularly the right to life under Article 21, support timely emergency healthcare but do not create an unconditional entitlement to unapproved experimental interventions. The objective is to facilitate potentially lifesaving treatment while preserving safeguards against avoidable harm, exploitation, and scientifically unjustified medical practice.

Legal note: The judgments discussed above include direct authorities on informed consent and emergency medical care, alongside comparative or analogous decisions. They should not be represented as rulings specifically establishing an emergency experimental-treatment approval pathway. The precise requirements depend on the jurisdiction, product category, and authorisation route.